Latest news with #bioproduction
Yahoo
3 days ago
- Business
- Yahoo
Winner of the 'Biotherapies and Bioproduction' call for projects under the France 2030 plan, EVerZom receives €3 million in government funding to industrialize its exosome bioproduction technology
Winner of the 'Biotherapies and Bioproduction' call for projects under the France 2030 plan, EVerZom receives €3 million in government funding to industrialize its exosome bioproduction technology Paris, June 17, 2025 – EVerZom, a French biopharmaceutical company pioneering exosome-based therapies for regenerative medicine applications, has announced it has received €3 million in funding as part of the France 2030 plan, through the 'Biotherapies and Bioproduction of Innovative Therapies' call for projects, operated by Bpifrance on behalf of the French government. This financial support will enable the company to accelerate the industrialization of its exosome bioproduction platform to develop its proprietary and co-developed drug candidates. Accelerating the transition to late-stage clinical production and commercialization This funding marks a key step in the company's industrial scale-up. It will notably allow for the scale-up of its exosome bioproduction technology in 50L GMP bioreactors, reaching a production level compatible with late-stage clinical phases and market launch. 'The French government 's support through the France 2030 'Biotherapies and Bioproduction' call is a strong recognition of our technology and industrial ambition. Thanks to this funding, we will secure a robust and scalable bioproduction process, which is essential to advance through late-stage clinical phases and prepare the market entry of our future proprietary or co-developed treatments,' said Jeanne Volatron, CEO of EVerZom. Exosomes at the heart of the development of promising new biotherapies Exosomes are tiny biological vesicles (30 to 150 nanometers) naturally secreted by cells. They play a key role in intercellular communication, transporting proteins, messenger RNAs, and other functional biomolecules between cells. EVerZom leverages exosomes derived from mesenchymal stem cells, known for their regenerative and immunomodulatory properties. Compared to the cells themselves, exosomes offer numerous advantages: increased stability, reduced variability, enhanced patient safety, and simplified logistics (direct hospital storage and immediate availability). EVerGel, EVerZom's first drug candidate for Crohn's disease EVerZom's flagship program, EVerGel, combines exosomes with an innovative hydrogel biomaterial, enabling prolonged release at the site of complex perianal fistulas—a debilitating condition associated with Crohn's disease that affects nearly 2 million patients worldwide. Initial preclinical results are highly promising: in a porcine model close to the human condition, EVerGel achieved complete healing in 87.5% of cases after 4 weeks, compared to just 12.5% in the control group. Thanks to these results, the drug candidate could enter clinical trials as early as 2026, with a target commercialization date for 2030. High potential far beyond the targeted indications Ultimately, the potential of exosome therapies to regenerate tissue and modulate inflammatory processes opens the door to new applications in a variety of fields, including neurodegenerative diseases, age-related disorders, and regenerative cosmetics. In this context, EVerZom has established around twenty global partnerships with players in human health, animal health, and cosmetics. Press contact : Florence Portejoie, FP2COM, 06 07 76 82 83, fportejoie@ About EVerZom Founded in 2019, EVerZom develops exosome-based treatments derived from mesenchymal stem cells, combined with biomaterials for targeted applications. With a proprietary technology for the production and purification of exosomes, EVerZom aims to address unmet medical needs in chronic inflammatory and degenerative diseases. The company relies on cutting-edge scientific expertise, a network of industrial and academic partners, and a development model focused on pharmaceutical quality and industrialization. This €3 million funding is part of the France 2030 plan, a French government initiative endowed with €54 billion to support breakthrough innovations and the emergence of technology champions in strategic sectors such as biotechnology. About France 2030 ✔ Embodies a dual ambition: to sustainably transform key sectors of our economy (health, energy, automotive, aerospace, and space) through technological innovation, and to position France not just as a player but as a leader in the world of tomorrow. From basic research to the emergence of an idea through to the production of a new product or service, France 2030 supports the entire innovation lifecycle up to industrialization. ✔ Is unprecedented in its scope: €54 billion are being invested to help our companies, universities, and research organizations successfully transition in these strategic sectors. The goal is to enable them to competitively tackle ecological and attractiveness challenges and foster the emergence of future leaders in our fields of excellence. France 2030 has two transversal objectives: dedicating 50% of its spending to the decarbonization of the economy and 50% to emerging players carrying innovations that are not harmful to the environment (in line with the Do No Significant Harm principle). ✔ Is implemented collectively: designed and deployed in consultation with economic, academic, local, and European stakeholders to determine strategic orientations and flagship actions. Project leaders are invited to submit their applications through open, rigorous, and selective procedures to benefit from State support. ✔ Is managed by the General Secretariat for Investment on behalf of the Prime Minister and implemented by the French Environment and Energy Management Agency (ADEME), the National Research Agency (ANR), Bpifrance, and the Banque des Territoires. More information: | @SGPI_avenir About the 'Innovations in Biotherapies and Bioproduction' call for projects The 'Innovations in Biotherapies and Bioproduction' call for projects is a support mechanism within the framework of the 'Biotherapies and Bioproduction of Innovative Therapies' acceleration strategy of France 2030, led by the Health Innovation Agency within the General Secretariat for Investment. Its objective is to catalyze and sustain excellence in biotherapy research by accelerating technology transfer and ensuring a constant flow of innovations from bench to bedside. About Bpifrance Bpifrance finances businesses at every stage of their development with loans, guarantees, and equity. It supports their innovation and international projects. Bpifrance also backs their export activities through a broad range of products. Advisory services, training, networking, and acceleration programs for startups, SMEs, and mid-caps are also part of the offering. Thanks to Bpifrance and its 50 regional offices, entrepreneurs benefit from a close, single, and efficient contact to support them and help them meet their challenges. More information: - - Follow us on X (formerly Twitter): @Bpifrance - @BpifrancePresse and on LinkedIn Attachment Everzom_PR_Winner_France_2030_VDEF
Yahoo
06-06-2025
- Business
- Yahoo
HTL Biotechnology inaugurates a new production line dedicated to sterile hyaluronic acid
JAVENÉ, France, June 6, 2025 /PRNewswire/ -- On the occasion of National Bioproduction and Biomedicines Day (JNBB), which enjoys the high patronage of the President of the French Republic, HTL Biotechnology confirms its position as a globalleader in the development and production of pharmaceutical-grade biopolymers, by inaugurating a new production unit dedicated to sterile hyaluronic acid at its Javené (Ille-et-Vilaine) site, a true flagship of French biomanufacturing. With over 30 years of expertise in biopolymers, HTL Biotechnology is reaffirming its commitment through this new production unit to the development of innovative therapeutic solutions for the medicine of today and tomorrow. The manufacture of sterile hyaluronic acid opens the way to new therapeutic opportunites . This cutting-edge process now makes it possible to combine hyaluronic acid with heat-sensitive active molecules, previously incompatible with traditional heat sterilization methods. Simultaneously, mastery of aseptic processes eliminates any risk of microbial contamination and ensures optimum pharmaceutical quality. This innovation marks a decisive step in the development of new combined formulations, bringing improved clinical benefits for patients in many fields, such as ophthalmology and drug delivery. This €12 million investment, part of HTL Biotechnology's €100 million 2022-2026 strategic plan, pursues two main goals: to explore new opportunities in bioproduction, and to strengthen the company's position as a key player in future applications of hyaluronic acid in healthcare. Production is scheduled to start in 2026, following qualification and validation of the industrial equipment. To guarantee the quality and efficiency of this new production unit, HTL Biotechnology has set up specific in-house training courses to instruct its staff in aseptic procedures and the handling of this new product. Because of the highly technical nature of this product, a team of ten specialists has been trained in the specific skills required for its production ensuring the highest quality standards. François Fournier, CEO of HTL Biotechnology, states: "I'm delighted with the prospects this investment gives us for further innovation in pharmaceutical-grade biopolymers. The breadth and complementarity of our portfolio is unique, and we are proud to be able to serve our customers even better. Thanks to this new unit, promising future applications can be explored, offering innovative solutions for the benefit of patients. I am delighted to be able to count on this new facility, which makes our historic Javené site a true flagship for French bioproduction." As an active member of France Biolead, HTL Biotechnology is proud to take part in the second National Biomanufacturing and Biomedicines Day, which this year enjoys the patronage of French President Emmanuel Macron. The company welcomes this recognition, which underscores the strategic importance of the French biomanufacturing and biomedical industry, at the heart of the challenges facing public health, and France. About HTL HTL Biotechnology is a French biotech company and world leader in the development and responsible biomanufacturing of pharmaceutical-grade biopolymers (Hyaluronic Acid, Polynucleotides and soon recombinant human collagen). These biopolymers are used by healthcare companies to develop treatments in a variety of leading therapeutic areas such as ophthalmology, dermatology, medical aesthetics and rheumatology. HTL Biotechnology recently strengthened its position as world leader in the development of pharmaceutical-grade biopolymers by acquiring, through its subsidiary HTL Biotechnology Innovation Inc. (HTL BII - New Jersey), a recombinant protein platform whose most advanced product is recombinant human collagen type III (rhCOL3) at a world-class scientific research center. To meet the world's growing need for biopolymers, the company also has subsidiaries in Asia and is building a neuromodulator production unit in the United States (HTL BMI - Massachusetts). Historically based in Javené (Brittany - France), the company brings together production, innovation, R&D , as well as quality activities on its site. HTL Biotechnology employs nearly 300 people worldwide. To learn more about HTL Biotechnology: LinkedIn: HTL Biotechnology X: @HTL_Biotech Instagram: @htlbiotechnology Press contact Nathalie Chevallon - HTL Biotechnologynchevallon@ View original content: SOURCE HTL Biotechnology
Yahoo
06-06-2025
- Business
- Yahoo
HTL Biotechnology inaugurates a new production line dedicated to sterile hyaluronic acid
JAVENÉ, France, June 6, 2025 /PRNewswire/ -- On the occasion of National Bioproduction and Biomedicines Day (JNBB), which enjoys the high patronage of the President of the French Republic, HTL Biotechnology confirms its position as a globalleader in the development and production of pharmaceutical-grade biopolymers, by inaugurating a new production unit dedicated to sterile hyaluronic acid at its Javené (Ille-et-Vilaine) site, a true flagship of French biomanufacturing. With over 30 years of expertise in biopolymers, HTL Biotechnology is reaffirming its commitment through this new production unit to the development of innovative therapeutic solutions for the medicine of today and tomorrow. The manufacture of sterile hyaluronic acid opens the way to new therapeutic opportunites . This cutting-edge process now makes it possible to combine hyaluronic acid with heat-sensitive active molecules, previously incompatible with traditional heat sterilization methods. Simultaneously, mastery of aseptic processes eliminates any risk of microbial contamination and ensures optimum pharmaceutical quality. This innovation marks a decisive step in the development of new combined formulations, bringing improved clinical benefits for patients in many fields, such as ophthalmology and drug delivery. This €12 million investment, part of HTL Biotechnology's €100 million 2022-2026 strategic plan, pursues two main goals: to explore new opportunities in bioproduction, and to strengthen the company's position as a key player in future applications of hyaluronic acid in healthcare. Production is scheduled to start in 2026, following qualification and validation of the industrial equipment. To guarantee the quality and efficiency of this new production unit, HTL Biotechnology has set up specific in-house training courses to instruct its staff in aseptic procedures and the handling of this new product. Because of the highly technical nature of this product, a team of ten specialists has been trained in the specific skills required for its production ensuring the highest quality standards. François Fournier, CEO of HTL Biotechnology, states: "I'm delighted with the prospects this investment gives us for further innovation in pharmaceutical-grade biopolymers. The breadth and complementarity of our portfolio is unique, and we are proud to be able to serve our customers even better. Thanks to this new unit, promising future applications can be explored, offering innovative solutions for the benefit of patients. I am delighted to be able to count on this new facility, which makes our historic Javené site a true flagship for French bioproduction." As an active member of France Biolead, HTL Biotechnology is proud to take part in the second National Biomanufacturing and Biomedicines Day, which this year enjoys the patronage of French President Emmanuel Macron. The company welcomes this recognition, which underscores the strategic importance of the French biomanufacturing and biomedical industry, at the heart of the challenges facing public health, and France. About HTL HTL Biotechnology is a French biotech company and world leader in the development and responsible biomanufacturing of pharmaceutical-grade biopolymers (Hyaluronic Acid, Polynucleotides and soon recombinant human collagen). These biopolymers are used by healthcare companies to develop treatments in a variety of leading therapeutic areas such as ophthalmology, dermatology, medical aesthetics and rheumatology. HTL Biotechnology recently strengthened its position as world leader in the development of pharmaceutical-grade biopolymers by acquiring, through its subsidiary HTL Biotechnology Innovation Inc. (HTL BII - New Jersey), a recombinant protein platform whose most advanced product is recombinant human collagen type III (rhCOL3) at a world-class scientific research center. To meet the world's growing need for biopolymers, the company also has subsidiaries in Asia and is building a neuromodulator production unit in the United States (HTL BMI - Massachusetts). Historically based in Javené (Brittany - France), the company brings together production, innovation, R&D , as well as quality activities on its site. HTL Biotechnology employs nearly 300 people worldwide. To learn more about HTL Biotechnology: LinkedIn: HTL Biotechnology X: @HTL_Biotech Instagram: @htlbiotechnology Press contact Nathalie Chevallon - HTL Biotechnologynchevallon@ View original content: SOURCE HTL Biotechnology
